Magnesium Sulfate Improves Some Risk Factors for Atherosclerosis in Patients Suffering from One or Two Coronary Artery Diseases: A Double-blind Clinical Trial Study

Ali Reza Sobhani,1 Hossein Farshidi,2 Fariba Azarkish,3 Mahdiya Eslami,2 Ebrahim Eftekhar,4 Mansoor Keshavarz,5 Nepton Soltani6 1Clinical Pathology Department, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; 2Cardiovascular Research Center, Hormozgan University of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sobhani AR, Farshidi H, Azarkish F, Eslami M, Eftekhar E, Keshavarz M, Soltani N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	atherosclerosis mgso4 fibrinogen crp homocysteine thyroid hormones Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/4e3d840a5f014393bde0bf1df256beac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4e3d840a5f014393bde0bf1df256beac
record_format	dspace
spelling	oai:doaj.org-article:4e3d840a5f014393bde0bf1df256beac2021-12-02T11:48:57ZMagnesium Sulfate Improves Some Risk Factors for Atherosclerosis in Patients Suffering from One or Two Coronary Artery Diseases: A Double-blind Clinical Trial Study1179-1438https://doaj.org/article/4e3d840a5f014393bde0bf1df256beac2020-09-01T00:00:00Zhttps://www.dovepress.com/magnesium-sulfate-improves-some-risk-factors-for-atherosclerosis-in-pa-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Ali Reza Sobhani,1 Hossein Farshidi,2 Fariba Azarkish,3 Mahdiya Eslami,2 Ebrahim Eftekhar,4 Mansoor Keshavarz,5 Nepton Soltani6 1Clinical Pathology Department, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; 2Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; 3Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; 4Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; 5Physiology Department, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran; 6Physiology Department, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranCorrespondence: Nepton SoltaniPhysiology Department, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranTel +98 9133251067Fax +98 36688597Email neptun.soltani@med.mui.ac.irPurpose: Given the beneficial effect of MgSO4 on the cardiovascular system, this study was designed to investigate the effect of MgSO4 administration on suppressing some atherosclerotic risk factors in moderate coronary artery disease patients with one or two atherosclerotic vessels.Patients and Methods: In a randomized double-blind placebo-controlled clinical trial study, 64 patients with moderate coronary artery disease (55– 69% stenosis) were selected according to angiography findings. Patients were divided into four groups including patients with one or two atherosclerotic vessels treated with MgSO4 (Mg-treated-VR1, Mg-treated-VR2, respectively), placebo treated patients with one or two atherosclerotic vessels (Control-VR1, Control-VR2, respectively). The patients received either placebo or MgSO4 supplement capsule containing 300 mg MgSO4 for six months on a daily basis. ESR, Ca/Mg ratio, urine Mg level, serum Mg, fibrinogen, homocysteine, uric acid, Na, K, Ca, CRP, T3, T4, TSH, BUN, and Cr concentrations were measured at baseline and every three months.Results: Serum T3, Ca, K, homocysteine, CRP, and Mg concentrations were significantly improved in Mg-treated groups compared to placebo groups.Conclusion: The results of this study showed that despite the slight change in serum magnesium level, oral administration of MgSO4for six months could slightly reduce the serum levels of some inflammatory and vascular factors in moderate coronary artery disease patients.Keywords: atherosclerosis, MgSO4, fibrinogen, CRP, homocysteine, thyroid hormonesSobhani ARFarshidi HAzarkish FEslami MEftekhar EKeshavarz MSoltani NDove Medical Pressarticleatherosclerosismgso4fibrinogencrphomocysteinethyroid hormonesTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 12, Pp 159-169 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	atherosclerosis mgso4 fibrinogen crp homocysteine thyroid hormones Therapeutics. Pharmacology RM1-950
spellingShingle	atherosclerosis mgso4 fibrinogen crp homocysteine thyroid hormones Therapeutics. Pharmacology RM1-950 Sobhani AR Farshidi H Azarkish F Eslami M Eftekhar E Keshavarz M Soltani N Magnesium Sulfate Improves Some Risk Factors for Atherosclerosis in Patients Suffering from One or Two Coronary Artery Diseases: A Double-blind Clinical Trial Study
description	Ali Reza Sobhani,1 Hossein Farshidi,2 Fariba Azarkish,3 Mahdiya Eslami,2 Ebrahim Eftekhar,4 Mansoor Keshavarz,5 Nepton Soltani6 1Clinical Pathology Department, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; 2Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; 3Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; 4Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; 5Physiology Department, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran; 6Physiology Department, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranCorrespondence: Nepton SoltaniPhysiology Department, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranTel +98 9133251067Fax +98 36688597Email neptun.soltani@med.mui.ac.irPurpose: Given the beneficial effect of MgSO4 on the cardiovascular system, this study was designed to investigate the effect of MgSO4 administration on suppressing some atherosclerotic risk factors in moderate coronary artery disease patients with one or two atherosclerotic vessels.Patients and Methods: In a randomized double-blind placebo-controlled clinical trial study, 64 patients with moderate coronary artery disease (55– 69% stenosis) were selected according to angiography findings. Patients were divided into four groups including patients with one or two atherosclerotic vessels treated with MgSO4 (Mg-treated-VR1, Mg-treated-VR2, respectively), placebo treated patients with one or two atherosclerotic vessels (Control-VR1, Control-VR2, respectively). The patients received either placebo or MgSO4 supplement capsule containing 300 mg MgSO4 for six months on a daily basis. ESR, Ca/Mg ratio, urine Mg level, serum Mg, fibrinogen, homocysteine, uric acid, Na, K, Ca, CRP, T3, T4, TSH, BUN, and Cr concentrations were measured at baseline and every three months.Results: Serum T3, Ca, K, homocysteine, CRP, and Mg concentrations were significantly improved in Mg-treated groups compared to placebo groups.Conclusion: The results of this study showed that despite the slight change in serum magnesium level, oral administration of MgSO4for six months could slightly reduce the serum levels of some inflammatory and vascular factors in moderate coronary artery disease patients.Keywords: atherosclerosis, MgSO4, fibrinogen, CRP, homocysteine, thyroid hormones
format	article
author	Sobhani AR Farshidi H Azarkish F Eslami M Eftekhar E Keshavarz M Soltani N
author_facet	Sobhani AR Farshidi H Azarkish F Eslami M Eftekhar E Keshavarz M Soltani N
author_sort	Sobhani AR
title	Magnesium Sulfate Improves Some Risk Factors for Atherosclerosis in Patients Suffering from One or Two Coronary Artery Diseases: A Double-blind Clinical Trial Study
title_short	Magnesium Sulfate Improves Some Risk Factors for Atherosclerosis in Patients Suffering from One or Two Coronary Artery Diseases: A Double-blind Clinical Trial Study
title_full	Magnesium Sulfate Improves Some Risk Factors for Atherosclerosis in Patients Suffering from One or Two Coronary Artery Diseases: A Double-blind Clinical Trial Study
title_fullStr	Magnesium Sulfate Improves Some Risk Factors for Atherosclerosis in Patients Suffering from One or Two Coronary Artery Diseases: A Double-blind Clinical Trial Study
title_full_unstemmed	Magnesium Sulfate Improves Some Risk Factors for Atherosclerosis in Patients Suffering from One or Two Coronary Artery Diseases: A Double-blind Clinical Trial Study
title_sort	magnesium sulfate improves some risk factors for atherosclerosis in patients suffering from one or two coronary artery diseases: a double-blind clinical trial study
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/4e3d840a5f014393bde0bf1df256beac
work_keys_str_mv	AT sobhaniar magnesiumsulfateimprovessomeriskfactorsforatherosclerosisinpatientssufferingfromoneortwocoronaryarterydiseasesadoubleblindclinicaltrialstudy AT farshidih magnesiumsulfateimprovessomeriskfactorsforatherosclerosisinpatientssufferingfromoneortwocoronaryarterydiseasesadoubleblindclinicaltrialstudy AT azarkishf magnesiumsulfateimprovessomeriskfactorsforatherosclerosisinpatientssufferingfromoneortwocoronaryarterydiseasesadoubleblindclinicaltrialstudy AT eslamim magnesiumsulfateimprovessomeriskfactorsforatherosclerosisinpatientssufferingfromoneortwocoronaryarterydiseasesadoubleblindclinicaltrialstudy AT eftekhare magnesiumsulfateimprovessomeriskfactorsforatherosclerosisinpatientssufferingfromoneortwocoronaryarterydiseasesadoubleblindclinicaltrialstudy AT keshavarzm magnesiumsulfateimprovessomeriskfactorsforatherosclerosisinpatientssufferingfromoneortwocoronaryarterydiseasesadoubleblindclinicaltrialstudy AT soltanin magnesiumsulfateimprovessomeriskfactorsforatherosclerosisinpatientssufferingfromoneortwocoronaryarterydiseasesadoubleblindclinicaltrialstudy
_version_	1718395225364234240

Magnesium Sulfate Improves Some Risk Factors for Atherosclerosis in Patients Suffering from One or Two Coronary Artery Diseases: A Double-blind Clinical Trial Study

Ejemplares similares